A preclinical study showed that FGFR inhibitors increased anti-PD-1 treatment efficacy in an FGFR3 mutant-driven murine high-grade NMIBC model by abrogating ICI-induced regulatory T cell (Treg) expansion in the tumor microenvironment [9]. The gene discussed is FGFR3; the disease is neoplasm.